Here is my daily post over there at that other pla
Post# of 5066
Posted On: 07/28/2013 9:24:46 AM
Here is my daily post over there at that other place:
To be clear about something, the HemXellerate product (that from which HemaXellerate is derived) is an Autologous SVF therapy. This means the cells used in this therapy are derived from a patient’s fat by way of liposuction which then undergo patented processes to finally arrive at the required state. The cells utilized in this therapy are not embryonic stem cells.
Because of the safety and ease of SVF administration—something that has already been established throughout the scientific & medical community through various types of successful procedures—it is expected that the HemXellerate therapy will be widely accepted as a successful alternative treatment to the various ailments Regen Biopharma intend to counter by way of their inventions.
Moreover, using SVF as a source of stem cells is more than forty years old; the practice of doing such has been carefully studied and documented in a plethora of publications. In fact, liposuction is performed routinely now and safety of this procedure has been previously published for rheumatoid arthritis in a 13 patient study in which patients were monitored for over one year where 80% improvement and no serious side effects were found.
So what’s the caveat? Frankly, I haven’t found one. In the world of fighting diseases, HemXellerate is very, very exciting.
That said, where is Regen with their advancements in HemaXellerate? The US Trademark is complete, the Q&A with the FDA is most likely satisfied and announcement for initiation of human trials with the likelihood Orphan Drug Status to be announced any day now. That is fact, an educated guess and a humble yet educated opinion.
They are keeping true to their timeline for the most part. Which is very, very ambitious but, too, very attainable with the great minds working behind the scenes to see all this come to fruition. And that does include David Koos. Regardless of what anyone says about him.
Given that the HemXellerate therapy has the potential to treat several if not many diseases in a trillion dollar pharmaceutical market, the monetary potential for this little company, based on their stem cell therapy alone is huge.
If I am correct with my suspicions that Orphan Drug Status for Hema is being established/finalized (however you want to put it) it will very soon be like Manna from Heaven for the company as that should be when the Whales jump in. Since, after all, it looks pretty darn good out yonder in the world of marketing when you are standing slap dab on the apex of the OD foothill.
Translated: It will start raining $$$ from those forces known as Venture Capitalists. Then it won’t be so east for this stock to be manipulated the way it is. And, those of us that have been long invested in this can finally start to see a return on our investment.
And that is before a negotiation with a BP is solidified.
Which brings me to my next point: When this stock finally does what it should be doing, there will be no need for the added dilution as outlined in the PRELIMINARY filing for the 3 billion increase for the Min technology. You know, that technology that no one else possesses, and does little thing with suppressing nasty little cancer genes. A technology invented by a doctor whose scientific appointments include but are not limited to:
Associate Professor, Department of Surgery
Associate Professor, Department of Pathology
Assocaite Professor, Department of Oncology
Immunologist, London Health Sciences Centre
Scientist, Lawson Health Research Institute
Who has received funding by such folk as Roche, the Canadian Institutes of Health, Lawson Research Institute & The Canadian Breast Cancer Fund to name a few.
No, Dr. Min might not know a little bit more about this science than the average Joe, might he?
Have I mentioned that efficacy has long since been proven in this science by the way?
In terms of what financial promise that means for Bio-Matrix Scientific group, I can’t even get my head wrapped around that figure yet. It’s a whole lot more than that nice chunk of change attached to the HemXellerate.
It infuriates me to see this company bashed as a scam. Or people question the validity of the undertakings. The composition of doctors alone is phenomenal. The advancements they have made and are currently fine tuning in the world of medicine are, well...
to da moooooooooon!
There is my one post for the day.
LONG BMSN, ENTB & MEDS!
To be clear about something, the HemXellerate product (that from which HemaXellerate is derived) is an Autologous SVF therapy. This means the cells used in this therapy are derived from a patient’s fat by way of liposuction which then undergo patented processes to finally arrive at the required state. The cells utilized in this therapy are not embryonic stem cells.
Because of the safety and ease of SVF administration—something that has already been established throughout the scientific & medical community through various types of successful procedures—it is expected that the HemXellerate therapy will be widely accepted as a successful alternative treatment to the various ailments Regen Biopharma intend to counter by way of their inventions.
Moreover, using SVF as a source of stem cells is more than forty years old; the practice of doing such has been carefully studied and documented in a plethora of publications. In fact, liposuction is performed routinely now and safety of this procedure has been previously published for rheumatoid arthritis in a 13 patient study in which patients were monitored for over one year where 80% improvement and no serious side effects were found.
So what’s the caveat? Frankly, I haven’t found one. In the world of fighting diseases, HemXellerate is very, very exciting.
That said, where is Regen with their advancements in HemaXellerate? The US Trademark is complete, the Q&A with the FDA is most likely satisfied and announcement for initiation of human trials with the likelihood Orphan Drug Status to be announced any day now. That is fact, an educated guess and a humble yet educated opinion.
They are keeping true to their timeline for the most part. Which is very, very ambitious but, too, very attainable with the great minds working behind the scenes to see all this come to fruition. And that does include David Koos. Regardless of what anyone says about him.
Given that the HemXellerate therapy has the potential to treat several if not many diseases in a trillion dollar pharmaceutical market, the monetary potential for this little company, based on their stem cell therapy alone is huge.
If I am correct with my suspicions that Orphan Drug Status for Hema is being established/finalized (however you want to put it) it will very soon be like Manna from Heaven for the company as that should be when the Whales jump in. Since, after all, it looks pretty darn good out yonder in the world of marketing when you are standing slap dab on the apex of the OD foothill.
Translated: It will start raining $$$ from those forces known as Venture Capitalists. Then it won’t be so east for this stock to be manipulated the way it is. And, those of us that have been long invested in this can finally start to see a return on our investment.
And that is before a negotiation with a BP is solidified.
Which brings me to my next point: When this stock finally does what it should be doing, there will be no need for the added dilution as outlined in the PRELIMINARY filing for the 3 billion increase for the Min technology. You know, that technology that no one else possesses, and does little thing with suppressing nasty little cancer genes. A technology invented by a doctor whose scientific appointments include but are not limited to:
Associate Professor, Department of Surgery
Associate Professor, Department of Pathology
Assocaite Professor, Department of Oncology
Immunologist, London Health Sciences Centre
Scientist, Lawson Health Research Institute
Who has received funding by such folk as Roche, the Canadian Institutes of Health, Lawson Research Institute & The Canadian Breast Cancer Fund to name a few.
No, Dr. Min might not know a little bit more about this science than the average Joe, might he?
Have I mentioned that efficacy has long since been proven in this science by the way?
In terms of what financial promise that means for Bio-Matrix Scientific group, I can’t even get my head wrapped around that figure yet. It’s a whole lot more than that nice chunk of change attached to the HemXellerate.
It infuriates me to see this company bashed as a scam. Or people question the validity of the undertakings. The composition of doctors alone is phenomenal. The advancements they have made and are currently fine tuning in the world of medicine are, well...
to da moooooooooon!
There is my one post for the day.
LONG BMSN, ENTB & MEDS!
(0)
(0)RIVULET MEDIA INC. (RIVU) Stock Research Links
Scroll down for more posts ▼